Journal
CANCER LETTERS
Volume 299, Issue 2, Pages 130-136Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.08.011
Keywords
Vascular endothelial growth factor; Osteopontin; Tumor; Angiogenesis; Metastasis
Categories
Funding
- National Natural Science Foundation of China
- Ministry of Science & Technology of China
- National Key Project for Infectious Diseases
- National Key project for New Drug Development and Manufacture
- Beijing and Shanghai Commission of Science Technology
- Ministry of Education of China
- Shanghai Commission of Education for excellent research team in Oncology
- Shanghai Key Project in Oncology
- Shanghai Rising-Star Program
- Dongfang Scholar
Ask authors/readers for more resources
Both vascular endothelial growth factor A (VEGF) and osteopontin (OPN) can directly induce tumor angiogenesis, which is essential for the growth and metastasis of solid tumors. Here we engineered a bispecific antibody (VEGF/OPN-BsAb) using the anti-VEGF-A antibody bevacizumab and the anti-OPN antibody hu1A12. Compared with hu1Al2 alone and bevacizumab alone, VEGF/OPN-BsAb was significantly more effective in inhibiting tumor angiogenesis in a highly metastatic human hepatocellular carcinoma nude mouse model. Further study demonstrated that VEGF/OPN-BsAb could effectively suppress primary tumor growth and metastasis to lungs, suggesting that it might be a promising therapeutic agent for treatment of metastatic cancer. (c) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
